

Clinical Trial Protocol

Iranian Registry of Clinical Trials

21 Jun 2026

Evaluation of the effect of melatonin supplementation on Insulin metabolism markers, parameters of oxidative stress and gene expression of PPAR- γ & ox-LDL in patients with diabetic nephropathy

Protocol summary

Study aim

Evaluation of the effect of melatonin supplementation on Insulin metabolism markers, parameters of oxidative stress and gene expression of PPAR- γ & ox-LDL in patients with diabetic nephropathy

Design

In this research, 60 patients with diabetic nephropathy who are eligible will be selected. Participants are randomly divided into two groups of intervention and control by computer software. The design of the study is the parallel blind randomized clinical trial.

Settings and conduct

60 patients with diabetic nephropathy who are eligible and referred to kidney clinic of Beheshti hospital affiliated to Kashan University of Medical Sciences, Kashan, Iran will be selected. Fasting blood samples will be taken at baseline and after 12 weeks of intervention.

Participants/Inclusion and exclusion criteria

Diabetic nephropathy patients with GFR between 15 and 89 ml / min, moderate blood pressure, lack of willingness to cooperate, non-use of fluvoxamine and any antioxidant supplement, non-cardiovascular disease, cancer, inflammatory diseases, autoimmune and hyper, or Hypothyroidism, Lack of lactation and pregnancy, lack of working in the night shift, the absence of a specific disease that leads to hospitalization, lack of smoking and alcohol consumption, absence of urinary tract infection and any other proteinuria causes.

Intervention groups

Patients will be assigned to receive either melatonin (intervention group: n=30) or placebo (control group: n=30).

Main outcome variables

Insulin resistance

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20150606022562N5**

Registration date: **2018-12-08, 1397/09/17**

Registration timing: **registered_while_recruiting**

Last update: **2018-12-08, 1397/09/17**

Update count: **0**

Registration date

2018-12-08, 1397/09/17

Registrant information

Name

Fereshteh Bahmani

Name of organization / entity

Kashan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 31 5554 0021

Email address

fbahmani@kaums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2018-11-11, 1397/08/20

Expected recruitment end date

2019-02-09, 1397/11/20

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effect of melatonin supplementation on Insulin metabolism markers, parameters of oxidative stress and gene expression of PPAR- γ & ox-LDL in patients with diabetic nephropathy

Public title

The effect of melatonin in patients with diabetic nephropathy

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

GFR 15 to 89 ml per minute Moderate blood pressure (systolic pressure 140-160 and diastolic pressure 80-100 mmHg) No specific cardiovascular disease, cancer, inflammatory diseases, autoimmune and hyper or hypothyroidism Non-presence of urinary tract infection and other factors of proteinuria

Exclusion criteria:

Special illness that leads to hospitalization. High blood pressure (systolic pressure upper than 160 and diastolic pressure upper than 100 mmHg) Unwillingness to cooperate Taking fluvoxamine and any antioxidant supplement Working at night shifts Smoking and alcohol consumption Breastfeeding and pregnancy

Age

From **40 years** old to **85 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

Sample size

Target sample size: **60**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization will be performed with simple method and random numbers generated by computer software.

Blinding (investigator's opinion)

Double blinded

Blinding description

In this study, participants, researchers, data collectors, evaluators and data analyzers are not aware of which group is placebo or supplemented melatonin groups.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Kashan university of medical sciences and health services

Street address

Kashan University of Medical Sciences, Ravand road

City

Kashan

Province

Isfahan

Postal code

8715988141

Approval date

2018-11-05, 1397/08/14

Ethics committee reference number

IR.KAUMS.MEDNT.REC.1397.64

Health conditions studied

1

Description of health condition studied

diabetic nephropathy

ICD-10 code

N08.3*

ICD-10 code description

Glomerular disorders in diabetes mellitus (E10-E14 with common fourth character .2†)

Primary outcomes

1

Description

Insulin

Timepoint

At the beginning of the study and 12 weeks after intervention.

Method of measurement

Elisa kit

2

Description

Insulin resistance

Timepoint

At the beginning of the study and 12 weeks after intervention.

Method of measurement

HOMA formula

Secondary outcomes

1

Description

Triglyceride

Timepoint

At the beginning of the study and 12 weeks after intervention

Method of measurement

Enzymatic kit

2

Description

HDL cholesterol

Timepoint

At the beginning of the study and 12 weeks after intervention

Method of measurement

Enzymatic kit

3

Description

Total cholesterol

Timepoint

At the beginning of the study and 12 weeks after intervention

Method of measurement

Enzymatic kit

4

Description

QUICKI

Timepoint

At the beginning of the study and 12 weeks after intervention

Method of measurement

Calculation using QUICKI formula

5

Description

plasma Malondialdehyde

Timepoint

At the beginning of the study and 12 weeks after intervention

Method of measurement

by Spectrophotometry method

6

Description

plasma protein carbonyl

Timepoint

At the beginning of the study and 12 weeks after intervention

Method of measurement

by Spectrophotometry method

7

Description

plasma total Gluthatione

Timepoint

At the beginning of the study and 12 weeks after intervention

Method of measurement

by Spectrophotometry method

8

Description

plasma total antioxidant capacity

Timepoint

At the beginning of the study and 12 weeks after intervention

Method of measurement

by Spectrophotometry method

9

Description

gene expression of PPAR-γ

Timepoint

At the beginning of the study and 12 weeks after intervention

Method of measurement

Real-Time PCR method

10

Description

gene expression of ox-LDL

Timepoint

At the beginning of the study and 12 weeks after intervention

Method of measurement

Real-Time PCR method

11

Description

C reactive protein

Timepoint

At the beginning of the study and 12 weeks after intervention

Method of measurement

by turbidimetric method

12

Description

Nitric oxide

Timepoint

At the beginning of the study and 12 weeks after intervention

Method of measurement

by Spectrophotometry method

Intervention groups

1

Description

Intervention group: Taking 10 mg melatonin at night for 12 weeks

Category

Treatment - Drugs

2**Description**

Control group: Taking placebo for 12 weeks

Category

Placebo

Recruitment centers1**Recruitment center****Name of recruitment center**

Beheshti hospital

Full name of responsible person

Dr. Alireza Soleymani

Street address

Qotb -e Ravandi Blvd.

City

Kashan

Province

Isfahan

Postal code

87159/81151

Phone

+98 31 5554 0026

Fax**Email**

beheshthospital@kaums.ac.ir

Sponsors / Funding sources1**Sponsor****Name of organization / entity**

Kashan University of Medical Sciences

Full name of responsible person

Dr. Hamid Reza Banafshe

Street address

Qotb -e Ravandi Blvd.

City

Kashan

Province

Isfahan

Postal code

8715988141

Phone

+98 31 5554 2999

Email

banafsheh_h@kaums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Kashan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding*empty***Country of origin****Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Kashan University of Medical Sciences

Full name of responsible person

Dr. Fereshte Bahmani

Position

Associate Professor/ Academic staff member of the Department of Clinical Biochemistry

Latest degree

Ph.D.

Other areas of specialty/work

Biochemistry

Street address

Medical Faculty, Kashan University of Medical Sciences, Ravand road

City

Kashan

Province

Isfahan

Postal code

8715988141

Phone

+98 31 5554 0021

Email

bahmani@kaums.ac.ir

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Kashan University of Medical Sciences

Full name of responsible person

Dr. Fereshte Bahmani

Position

Associate Professor/ Academic staff member of the Department of Clinical Biochemistry

Latest degree

Ph.D.

Other areas of specialty/work

Biochemistry

Street address

Medical Faculty, Kashan University of Medical Sciences, Ravand road

City

Kashan

Province

Isfahan

Postal code

8715988141

Phone

+98 31 5554 0021

Email

bahmani@kaums.ac.ir

Person responsible for updating data

Contact

Name of organization / entity

Kashan University of Medical Sciences

Full name of responsible person

Dr. Fereshteh Bahmani

Position

Associate Professor/ Academic staff member of the
Department of Clinical Biochemistry

Latest degree

Ph.D.

Other areas of specialty/work

Biochemistry

Street address

Medical Faculty, Kashan University of Medical
Sciences, Ravand road

City

Kashan

Province

Isfahan

Postal code

8715988141

Phone

+98 31 5554 0021

Email

bahmani@kaums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to
make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to
make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to
make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to
make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to
make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to
make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to
make this available